Blood:霍奇金淋巴瘤肿瘤微环境中,CD4+效应T细胞耗竭、调节T细胞富集

2018-06-08 MedSci MedSci原创

中心点:新确诊的原发性cHLs伴随CD4+Th1极化调节T细胞和分化的效应T细胞增多。原发性cHLs表现出两种主要的免疫抑制互补——PD-1+Th1效应细胞耗竭和PD-1-Th1调节T细胞活化。摘要:经典型霍奇金淋巴瘤(cHL)患者抗肿瘤免疫反应失效。霍奇金RS(HRS)细胞有多种逃脱免疫细胞的机制,包括9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2)遗传变异、PD-1配体过

中心点:

新确诊的原发性cHLs伴随CD4+Th1极化调节T细胞和分化的效应T细胞增多。

原发性cHLs表现出两种主要的免疫抑制互补——PD-1+Th1效应细胞耗竭和PD-1-Th1调节T细胞活化。

摘要:

经典型霍奇金淋巴瘤(cHL)患者抗肿瘤免疫反应失效。霍奇金RS(HRS)细胞有多种逃脱免疫细胞的机制,包括9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2)遗传变异、PD-1配体过表达、相关T细胞耗竭以及异常抗体呈现的额外的结构基础。临床上成功封闭cHL患者的PD-1提示肿瘤微环境(TME)包括可逆性耗竭T效应细胞(Teff)。但是,在HRS细胞β2M/I型MHC丢失的患者中可观察到持续反应,提示非-CD8+T细胞可能也介导PD-1封闭效应。上述发现强调需对cHL肿瘤微环境进行详细分析。

研究人员同时评估来源于诊断性cHL活检和对照反应淋巴结/扁桃体(RLNT)样本的细胞悬液。免疫细胞亚型的精确表型显示cHLs和RLNTs之间存在显着差异。cHL的肿瘤微环境中CD4+T细胞富集伴随HRS细胞I型MHC表达频繁丧失。

研究人员还发现,在cHLs中,Th1极化的T辅助细胞和调节T细胞同时扩增。cHL Th1调节T细胞少量表达或不表达PD-1,而Th1辅助T细胞为PD-1+。

PD-1表达差异、Th1极化的CD4+调节T细胞的可能功能和T辅助细胞耗竭或许是cHL免疫抑制的互补机制。

原始出处:

Fathima Zumla Cader,et al. Mass cytometry of Hodgkin lymphoma reveals a CD4+ exhausted T-effector and T-regulatory cell rich microenvironment. Blood  2018  :blood-2018-04-843714;  doi: https://doi.org/10.1182/blood-2018-04-843714

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2029468, encodeId=7a852029468b4, content=<a href='/topic/show?id=21a71803689' target=_blank style='color:#2F92EE;'>#T细胞耗竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18036, encryptionId=21a71803689, topicName=T细胞耗竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat May 25 03:50:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864232, encodeId=2c3f1864232f4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Mar 29 05:50:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696233, encodeId=1247169623301, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Wed Nov 14 12:50:00 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652585, encodeId=759516525855d, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Feb 09 03:50:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322674, encodeId=71973226e4ea, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 09 06:42:47 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322524, encodeId=711e3225240c, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jun 08 14:29:02 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2029468, encodeId=7a852029468b4, content=<a href='/topic/show?id=21a71803689' target=_blank style='color:#2F92EE;'>#T细胞耗竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18036, encryptionId=21a71803689, topicName=T细胞耗竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat May 25 03:50:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864232, encodeId=2c3f1864232f4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Mar 29 05:50:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696233, encodeId=1247169623301, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Wed Nov 14 12:50:00 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652585, encodeId=759516525855d, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Feb 09 03:50:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322674, encodeId=71973226e4ea, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 09 06:42:47 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322524, encodeId=711e3225240c, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jun 08 14:29:02 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2019-03-29 qidongfanjian
  3. [GetPortalCommentsPageByObjectIdResponse(id=2029468, encodeId=7a852029468b4, content=<a href='/topic/show?id=21a71803689' target=_blank style='color:#2F92EE;'>#T细胞耗竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18036, encryptionId=21a71803689, topicName=T细胞耗竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat May 25 03:50:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864232, encodeId=2c3f1864232f4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Mar 29 05:50:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696233, encodeId=1247169623301, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Wed Nov 14 12:50:00 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652585, encodeId=759516525855d, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Feb 09 03:50:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322674, encodeId=71973226e4ea, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 09 06:42:47 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322524, encodeId=711e3225240c, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jun 08 14:29:02 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2029468, encodeId=7a852029468b4, content=<a href='/topic/show?id=21a71803689' target=_blank style='color:#2F92EE;'>#T细胞耗竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18036, encryptionId=21a71803689, topicName=T细胞耗竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat May 25 03:50:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864232, encodeId=2c3f1864232f4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Mar 29 05:50:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696233, encodeId=1247169623301, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Wed Nov 14 12:50:00 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652585, encodeId=759516525855d, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Feb 09 03:50:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322674, encodeId=71973226e4ea, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 09 06:42:47 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322524, encodeId=711e3225240c, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jun 08 14:29:02 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2019-02-09 xuyu
  5. [GetPortalCommentsPageByObjectIdResponse(id=2029468, encodeId=7a852029468b4, content=<a href='/topic/show?id=21a71803689' target=_blank style='color:#2F92EE;'>#T细胞耗竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18036, encryptionId=21a71803689, topicName=T细胞耗竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat May 25 03:50:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864232, encodeId=2c3f1864232f4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Mar 29 05:50:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696233, encodeId=1247169623301, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Wed Nov 14 12:50:00 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652585, encodeId=759516525855d, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Feb 09 03:50:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322674, encodeId=71973226e4ea, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 09 06:42:47 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322524, encodeId=711e3225240c, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jun 08 14:29:02 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2018-06-09 kafei

    学习了谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2029468, encodeId=7a852029468b4, content=<a href='/topic/show?id=21a71803689' target=_blank style='color:#2F92EE;'>#T细胞耗竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18036, encryptionId=21a71803689, topicName=T细胞耗竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat May 25 03:50:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864232, encodeId=2c3f1864232f4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Mar 29 05:50:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696233, encodeId=1247169623301, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Wed Nov 14 12:50:00 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652585, encodeId=759516525855d, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Feb 09 03:50:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322674, encodeId=71973226e4ea, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 09 06:42:47 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322524, encodeId=711e3225240c, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jun 08 14:29:02 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2018-06-08 1ddf0692m34(暂无匿称)

    学习了.长知识

    0

相关资讯

NCCN临床实践指南:霍奇金淋巴瘤(2018.V3)

2018年4月,美国国家综合癌症网络(NCCN)发布了霍奇金淋巴瘤指南,2018年第3版,指南更新照样如下: 诊断和检查 经典霍奇金淋巴瘤的临床分期 完成治疗后随访和副作用监测 耐药或疑似复发经典型霍奇金淋巴瘤 I–II期典型霍奇金淋巴瘤不利的风险因素 系统治疗原则 放射治疗原则 PET-5绩点量表 复发或难治性疾病的系统治疗原则 老年典型霍奇金淋巴瘤的管理 分期

Blood:Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人:客观反应率高达100%!

Brentuximab vedotin是将一种微管抑制剂和CD30抗体通过共价键相连的新型抗体偶联药物(ADC),目前已被FDA批准用于霍奇金淋巴瘤(HL)和间变性大细胞淋巴瘤(ALCL)的后线治疗。近日,美国MD Anderson癌症中心Fanale等人开展了一项I期临床试验,旨在探索Brentuximab vedotin在ALCL一线治疗中的疗效和安全性,其结果近日发表于Blood杂志。

FDA扩大Adcetris适应症至III期或IV期经典霍奇金淋巴瘤

美国食品和药物管理局已批准Adcetris(brentuximab vedotin)用于先前治疗或未经治疗的III期或IV期经典霍奇金淋巴瘤(cHL)的成人患者。

2018 ESMO临床实践指南:霍奇金淋巴瘤的诊断,治疗和随访

2018年5月,欧洲肿瘤内科学会(ESMO)发布了霍奇金淋巴瘤的诊断,治疗和随访指南,文章主要内容涉及霍奇金淋巴瘤的发病率和流行病学,诊断,疾病分期和风险评估,治疗,治疗反应评估以及随访和并发症监测等。

Blood:Brentuximab vedotin联合苯达莫司汀作为一线补救疗法用于复发性/难治性HL的疗效和安全性

自体干细胞移植(ASCT)是一线化疗后复发/难治性霍奇金淋巴瘤(HL)的标准治疗。预ASCT补救化疗获得完全缓解(CR)预示ASCT后可取得良好预后。Ann S. LaCasce等人开展1/2期研究评估Brentuximab vedotin联合苯达莫司汀作为一线补救疗法用于复发性/难治性HL的疗效和安全性。共招募55位患者(28位原发难治性、27位复发性)。用药方案:BV 1.8mgkg(第一天)

Blood:复发性/难治性霍奇金淋巴瘤的移植治疗管理

大多数霍奇金淋巴瘤(HL)患者可通过初试治疗得到治愈。另外高剂量的自体造血干细胞移植(AHCT)可治愈额外部分的复发性或难治性HL(rrHL)患者。PET阴性的完全缓解(CR)优于AHCT,对长期病程控制至关重要。有多种补救选择可供对比缓解率,而且可根据合并症和具体情况进行选择。放射治疗也可提高缓解率,对特定的患者来说也是一种重要的治疗选择。AHCT后用BV维持治疗有助于稳定高复发风险患者的病情,